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ABSTRACT 
Objectives: To investigate the mechanisms of losartan- and exercise training-induced 
improvements on endothelial dysfunction in heart failure. 
Design: Sprague-Dawley rats subjected to left coronary artery ligation inducing myocardial 
infarction and heart failure were randomized to losartan treatment, high-intensity exercise 
training, or both.  
Results: Losartan, but not exercise training, reduced the heart failure-associated elevation in 
left ventricular end-diastolic pressure (26±2 mmHg vs. 19±1 mmHg after losartan). In 
contrast, both exercise training and losartan improved exercise capacity, by 40% and 20%, 
respectively; no additional effects were observed when exercise training and losartan were 
combined. Aortic segments were mounted on a force transducer to determine vasorelaxation. 
Heart failure impaired endothelium-dependent vasorelaxation, observed as a 1.9-fold reduced 
response to acetylcholine (EC50). Exercise and losartan improved acetylcholine-mediated 
vasorelaxation to the same extent, but by different mechanisms. Exercise training upregulated 
the nitric oxide pathway, whereas losartan upregulated a non-nitric oxide or -prostacyclin 
pathway; possibly involving the endothelium-dependent hyperpolarizing factor. 
Conclusions: Both losartan and exercise training reversed endothelial dysfunction in heart 
failure; exercise training via nitric oxide-dependent vasorelaxation, and losartan via an 
unknown mechanism that may involve endothelium-dependent hyperpolarizing factor. Thus, 
the combined treatment activated an additional nitric oxide-independent mechanism that 
contributed to reduce endothelial dysfunction. 
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INTRODUCTION 
Endothelial dysfunction contributes to heart failure (HF) pathogenesis by increasing cardiac 
afterload and reducing muscle perfusion with subsequently reduced exercise capacity (1,2). It 
is characterized by a reduced capacity of the blood vessels to dilate and is caused by reduced 
availability of substances causing vascular smooth muscle relaxation. The main smooth 
muscle relaxant is endothelium-derived nitric oxide (NO), of which generation may be limited 
by substrate for production (L-arginine), limitation and deactivation of the catalyzer 
(endothelial NO synthase, eNOS) and scavenging of NO (oxidant status). However, 
independent of NO, also insufficient availability of endothelial-derived hyperpolarizing 
factors (EDHF) can contribute to decreased smooth muscle relaxation (7), although the exact 
cellular mechanism by which this occurs remains unknown.  
 
As such, restoration of endothelial function remains important for the management of HF. 
Both physical exercise and the angiotensin II type 1 receptor blocker (ARB) losartan are 
known to beneficially alter endothelial and overall health (4,5). Exercise training counteracts 
endothelial dysfunction by activating NO production by eNOS (1), and by improving work 
capacity and quality of life in HF patients (2,5-7), whereas losartan also favorably affects the 
outcome of HF (8,9), at least partly by enhancing endothelial-dependent vasorelaxation (10). 
Thus, both exercise training and losartan treatments may be advantageous for vascular and 
endothelial health in HF. However, the effect of a combination of exercise training and 
losartan in HF relative to treatments with either option alone remains poorly understood. 
 
The aim of this study was therefore to determine the effect of exercise training and losartan, 
either each alone or in combination, on the endothelial dysfunction in HF after myocardial 
infarction. Moreover, we also investigated the mechanisms by which endothelial dysfunction 
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was corrected. Our hypothesis was that both exercise training and losartan would contribute 
toward correcting endothelial function in HF, but by different endothelium-dependent 
mechanisms. 
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MATERIALS AND METHODS 
Study design 
Left coronary artery ligation leading to myocardial infarction and subsequent HF, or sham 
operation, as previously described (11,12), was performed in female Sprague-Dawley rats 
(Møllegaards Breeding Center Ltd, Denmark) during 1% isoflurane anaesthesia in 70% 
O2/30% N2O. Buprenorphine (0.05mg Temgesic, Reckitt and Coleman, Hull, UK) was given 
subcutaneously immediately and 10 hours after surgery. 7 days post-surgery, 2-dimensional 
short-axis echocardiography confirmed myocardial infarction. Rats were randomized to 6 
different groups with 8 in each group; see Table 1A. Losartan (2 g∙L-1 ad libitum, Merck & 
Co., Whitehouse Station, NJ) or placebo in the drinking water was initiated 1 week after the 
surgery, whereas exercise training was initiated 4 weeks after the surgery, to mimic a 
clinically relevant treatment strategy; controls remained sedentary. 48 hours after the last 
exercise session, subcutaneous anaesthesia was given (in mL: 0.33 haloperidol, 0.5 fentanyl, 
0.5 midazolam, 0.3 ketamine hydrochloride, 0.5 water) and a pressure microtip catheter (2-Fr 
size Millar, Millar Instruments, Houston, TX) was inserted into the right carotid artery and 
advanced to the heart, whereby left ventricular (LV) end-diastolic and peak systolic pressures 
were measured, before euthanasia. The investigation conforms with the Guide for the Care 
and Use of Laboratory Animals published by the US National Institutes of Health (NIH 
Publication No. 85-23, revised 1996), and was approved by the Institutional Review Board. 
 
Maximal oxygen uptake and exercise training 
After a 20-minute warm-up by running on a 25° inclined treadmill at ~50% of the maximal 
oxygen uptake (VO2max), the treadmill velocity was increased progressively every 2 minutes 
until exhaustion. Oxygen uptake was measured continuously in a custom-made metabolic 
chamber, and the highest recorded value was taken as a representation of VO2max. 
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The endurance exercise training was performed as previously described (11,12). After 10-
minutes of warm-up, rats were running uphill (25°) on a treadmill for 1.5 hours, alternating 
between 8 minutes at an exercise intensity corresponding to 85-90% of VO2max, and 2 minutes 
active recovery at 50-60%. Exercise was performed 5 days/week for 8 weeks, and VO2max was 
measured every week in the exercising animals to adjust running speed in order to maintain 
high intensity throughout the exercise period, whereas VO2max in sedentary rats was measured 
before and after the experimental period. 
 
Vascular function 
The abdominal aorta was carefully dissected with care taken to not touch the endothelium. 6 
2-3 mm long segments from each rat were connected to force transducers and immersed in a 
10 mL organ bath containing Krebs buffer, whereupon tension was increased stepwise to 1 
gram over 75 minutes. A modified high K+ (60 mM) Krebs buffer was added and washed out 
again, and tension was again stabilized to 1 gram, whereby a dose of phenylephrine (3∙10-4 M) 
was added before addition of acetylcholine (10-4 M) to ensure reactivity. After washing and 
stabilizing the segments once more, the following protocols A-F were initiated; see Table 1B. 
Briefly described, aorta segments were contracted with phenylephrine and relaxed with 
accumulating doses of either acetylcholine or Na+ nitroprusside (SNP), in the presence of 
superoxide dismutase (SOD) and/or indomethacin to inhibit superoxide and prostacyclin 
productions, respectively. After re-stabilizing and incubating the segments as described 
above, a second set of contractions and relaxations were initiated, but this time with the 
addition of 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ) or NG- nitro-L-arginine 
(LNNA) for 45 minutes to inhibit soluble guanylyl cyclase (sGC) and eNOS, respectively 
(Table 1B). The chemicals were purchased from Sigma-Aldrich, except ODQ (Cayman 
Chemical, Ann Arbor, MI). Dose–response curves and EC50–values (the agonist concentration 
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that evokes 50% of maximal dilatation) were obtained and areas under curves were calculated 
using the trapezoidal rule in Sigmaplot version 8.02. Although the abdominal aorta is a 
capacitor, and has little importance in the regulation of blood pressure, previous studies in our 
group have shown equal exercise-induced endothelial responses in the carotid artery as in the 
aorta (13). 
 
Statistical analysis 
Mann-Whitney U test determined differences in EC50–values, and a univariate repeated-
measures general linear model with the Scheffé post hoc test assessed differences in the 
relaxation responses. To identify changes in VO2max, the Friedman test for within-group 
comparisons over time and the Kruskal-Wallis test for between-group comparisons were used. 
p<0.05 was considered as significant. Data are presented as mean±SEM. 
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RESULTS 
HF 
In order to confirm development of HF after myocardial infarction due to left coronary artery 
ligation, we measured LV end-diastolic and peak-systolic pressures (LVEDP and LVPSP, 
respectively). We observed elevated LVEDP and reduced LVPSP in all post-myocardial 
infarction rats included in the study, and thus the presence of HF was confirmed (Table 2). 
Exercise training did not alter the LVEDP, although a small but insignificant reduction was 
noted. In contrast, losartan decreased LVEDP by 8 mmHg. None of the treatments corrected 
for abnormal LVPSP. 
 
VO2max 
HF was associated with a ~40% reduction in exercise capacity (VO2max) as compared to 
healthy sham-operated rats (Fig. 1). However, exercise training restored VO2max to levels 
comparable to sedentary sham-operated rats. The magnitude of the exercise effect was similar 
to that of healthy rats. Losartan alone also improved VO2max, but considerably less than 
exercise training (~20%), whereas the combination of losartan and exercise training did not 
result in any effect beyond that of exercise training alone. This suggests that exercise training 
may take out the potential for improvement, such that additive strategies for increasing 
VO2max have no further effects. Both sham-operated and HF rats that remained sedentary and 
did not receive losartan decreased VO2max over the course of the study. 
 
Acetylcholine-dependent vasorelaxation 
Endothelium-dependent vasorelaxation in the aorta was reduced in HF; indicating endothelial 
dysfunction, as evidenced by the 1.9-fold higher EC50, i.e. reduced sensitivity, in the response 
to acetylcholine in HF compared to sham-operated rats (Fig. 2A and B). Exercise training, 
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losartan, and the combination of losartan and exercise training improved vasorelaxation 2.8-
fold, 3.3-fold, and 3.4-fold, respectively (p<0.05 for all); thus, the combination of exercise 
training and losartan did not change the magnitude of improvement compared to either 
intervention alone. Furthermore, aorta segments of HF rats on losartan or exercise training 
also showed a trend toward higher sensitivity to acetylcholine than those of sedentary healthy 
rats, albeit it did not reach statistical significance. Exercise training in healthy rats also 
improved the acetylcholine sensitivity (EC50) and hence endothelial function. Maximal 
dilatation (Vmax) of the aorta tended to be reduced in HF (~18%, p<0.1), but restored by 
treatment with both losartan and exercise training (Fig. 2C). 
 
Acetylcholine-mediated vasorelaxation after addition of L-arginine and SOD 
Addition of 3 mM L-arginine improved vasorelaxation in untreated, sedentary HF rats, 
observed as a 1.9-fold increase in acetylcholine sensitivity (Fig. 2D). L-arginine-dependent 
effects were not seen in the other groups, although EC50 tended to improve in sham-operated 
sedentary rats, but this did not reach statistical significance (p=0.06).  
 
Incubation with 250 IU SOD increased sensitivity to acetylcholine in untreated, sedentary HF 
and sham-operated rats by 3.4-fold and 2.3-fold, respectively (Fig. 2E). No significant 
changes occurred in the remaining groups, although a trend for improved endothelial function 
was observed in all of them.  
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Addition of L-arginine or SOD did not affect Vmax in any of the groups (data not shown). 
Nonetheless, as shown in Fig. 2D and E, HF presents with a potential for improving 
acetylcholine-mediated vasorelaxation by interventions to increase L-arginine or to inhibit 
superoxides, which react with NO to form peroxynitrite. This potential is no longer observed 
in HF after treatment with exercise training or losartan. 
 
Acetylcholine-mediated vasorelaxation after inhibition of prostacyclin and NO 
productions 
Incubation with 10-5 M indomethacin revealed no further differences in vasorelaxation 
between the groups (Fig. 3A), suggesting that prostacyclin did not contribute to the observed 
vasorelaxation effects presented in Fig. 2. In contrast, inhibition of NO-synthesis by 10-4 M 
LNNA abolished the exercise-induced increase in vasorelaxation, whereas losartan-treated 
rats remained with a trend (p=0.12) towards greater vasorelaxation (Fig. 3B). Moreover, 
blocking sGC with 10-5 M ODQ before adding accumulating doses of acetylcholine abolished 
vasorelaxation and instead lead to a minor, but uniform contraction of 2-4% (Fig. 3C).  
 
Subtracting the area under these two curves from the area under the curve of the non-NO-
inhibited relaxation (curve 3A-(curves 3B+3C)) revealed that the exercise trained aorta 
segments relied ~50% more on NO for relaxation, compared to the sedentary groups (Fig. 
3D). This was observed in both sham-operated and HF rats. These pharmacological 
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maneuvers also suggest that losartan in contrast exerted its effect on endothelium-dependent 
vasorelaxation through a non-NO and non-prostacyclin-mediated effect; of which molecular 
identity remains unknown, but may involve EDHF. The reason this suggests EDHF as the 
mechanism is that it is the only known vasorelaxant downstream of acetylcholine and 
independent of NO and prostacyclin. As such, treatment with either losartan or exercise 
training reversed the endothelial dysfunction, but by different mechanisms, which were not 
additive when combined, suggesting a ceiling effect on endothelial-dependent vasorelaxation 
of either treatment alone. 
 
Finally, incubation with 250 IU SOD significantly (p<0.05) increased the 
LNNA/indomethacin-resistant vasorelaxation in all groups except sedentary HF rats on 
losartan (data not shown), whereas adding 10-4 M SNP to aorta segments incubated with 
LNNA and ODQ lead to ~100% and ~0% relaxation, respectively (data not shown). 
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DISCUSSION 
HF was associated with endothelial dysfunction in the abdominal aorta. However, the 
dysfunction was largely reversed by exercise training or by treatment with the ARB losartan, 
but by two distinct signaling pathways; exercise training through an NO-dependent effect and 
losartan through a non-NO- and non–prostacyclin effect; thus suggesting losartan may have 
activated EDHF. When both exercise training and losartan were combined, losartan did not 
inhibit the salutary effects of NO, and furthermore, it activated an additional pathway of 
vasoregulation that may become important in periods of exercise cessation, albeit the 
combination did not improve endothelial-dependent vasorelaxation further of either treatment 
alone. This may be explained by exercise training and losartan both individually inducing a 
near-maximal effect on acetylcholine-mediated endothelium-dependent vasorelaxation. 
Nonetheless, a combination of exercise training and losartan may provide the better strategy 
for long-term HF treatment as it allows periods of absence of exercise without compromising 
endothelial function, as well as preserving the independent effects of each treatment alone 
beyond the endothelium (7-9). 
 
Nitric oxide-dependent vasoregulation 
By inhibiting eNOS-mediated NO-production by LNNA, prostacyclin-production by 
indomethacin, and sGC-cyclic guanosine monophosphate (cGMP)-dependent vasorelaxation 
by ODQ, the relative contributions of these pathways were assessed. This showed that 
impaired vasorelaxation in HF was due to reduced endothelial NO-availability, and that 
exercise training mainly improved vasorelaxation by stimulating NO-availability in both 
healthy and HF rats. This has also been suggested previously (1,6,13). Exercise training in 
combination with losartan also improved endothelial function via an NO-dependent pathway; 
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as shown previously (14,15), whereas in contrast, losartan alone did not stimulate NO-
availability.  
 
It has been suggested that eNOS-inhibition by L-arginine antagonists may only affect the 
stimulated and not the basal NO-production (16). In line with this, addition of SOD in the 
presence of LNNA; an irreversible inhibitor with a slow dissociation rate (17), still stimulated 
the vasorelaxation, except in losartan-treated sedentary HF rats. This points to an inability to 
completely block the basal NO-production, but also suggests that losartan upregulated an 
endothelial-mediated NO- and prostacyclin-independent vasodilator, for which the molecular 
identity remains unknown, but may be EDHF. As such, although the combination of exercise 
training and losartan did not provide observable additive effects, the combination strategy 
may be important inasmuch as previous experiments have suggested that the exercise-induced 
NO-dependent vasodilation varies greatly and exists only transiently after an exercise session 
(18). Losartan may thus provide an additional pathway of vasorelaxation when the NO-
mediated regulation is low. 
 
Endothelial-mediated NO- and prostacyclin-independent vasorelaxation 
The foremost candidate for endothelial-mediated NO- and prostacyclin-independent 
vasoregulation is EDHF, but its molecular identity remains unclear and may encompass 
several factors originating from the endothelium (19); of which hydrogen sulfide (H2S) is a 
recent candidate (20). In HF, the contribution of EDHF relative to NO for inducing 
vasorelaxation is increased, partly because NO is reduced (21). This was also indicated in our 
study. The finding that losartan exerted an endothelium-dependent, but NO- and prostacyclin-
independent effect, i.e. an effect attributable to stimulated EDHF, is similar to that observed 
after angiotensin-converting enzyme (ACE) inhibition (22). Together, this suggests an 
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angiotensin II action that is not confined to the vascular smooth muscle cell, but may also 
involve the endothelium. 
 
Since blockade of the sGC-cGMP pathway by ODQ effectively removed both NO-dependent 
and endothelium-dependent but NO- and prostacyclin-independent; thus, possibly EDHF-
mediated, vasorelaxation, it opens up the possibility that NO and EDHF or its equivalent may 
initiate similar sGC-cGMP-dependent reactions in the smooth muscle cell. This is in line with 
reports of angiotensin II negatively affecting sGC independent of NO (23). Finally, we also 
observed that the NO- and prostacyclin-independent contribution to endothelium-mediated 
vasorelaxation was reduced when exercise training was introduced to HF rats on losartan, 
indicating that activated NO prevailed as the main vasodilator. 
 
Conclusion 
Endothelial dysfunction in HF was reversed by treatments involving exercise training and the 
ARB losartan, either alone or in combination. However, whereas exercise training improved 
endothelial function by restoring NO-production, losartan upregulated a different intra-
endothelial pathway that is NO- and prostacyclin-independent. When losartan and exercise 
training were combined, no additional vasorelaxation occurred, but NO prevailed as the main 
vasodilator. Nonetheless, losartan might activate an additional mechanism for vasorelaxation 
that supplements NO-dependent vasorelaxation, which may be important when and if NO 
production is compromised. 
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TABLES 
Table 1. Experimental interventions. 
A; Group assignment 
 Heart failure Losartan Exercise training 
SH SED PL - - - 
SH EX PL - - + 
HF SED PL + - - 
HF SED LOS + + - 
HF EX PL + - + 
HF EX LOS + + + 
    
B; Pharmacological interventions during recordings of vascular function 
 Pre-incubation Contraction Relaxation 2nd Pre-incubation 
A 3 mM L-Arg, 10-5 M Indo 3∙10-7 M Phe 10-9-3∙10-5 M Ach 10-5 M ODQ 
B 250 IU SOD, 10-5 M Indo 3∙10-7 M Phe 10-9-3∙10-5 M Ach 10-4 M LNNA 
C 250 IU SOD 3∙10-7 M Phe 10-9-3∙10-5 M Ach 10-5 M ODQ 
D 10-5 M Indo 3∙10-7 M Phe 10-9-3∙10-5 M Ach 10-4 M LNNA 
E Vehicle 3∙10-7 M Phe 10-9-3∙10-5 M Ach 10-4 M LNNA 
F Vehicle 3∙10-7 M Phe 10-9-3∙10-5 M SNP 10-5 M ODQ 
SH: sham operation; SED: sedentary; PL: placebo; EX: exercise training; HF: heart 
failure; LOS: losartan; L-Arg: L-arginine; Indo: indomethacin; SOD: superoxide 
dismutase; Phe: phenylephrine; Ach: acetylcholine; SNP: Na+ nitroprusside; ODQ: 
1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one; LNNA: NG-nitro-L-arginine. 
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Table 2. Left ventricular pressure recordings and infarct sizes. 
 Sham  HF 
 SED-PL EX-PL  SED-PL SED-LOS EX-PL EX-LOS 
 
LVEDP (mmHg) 
 
LVPSP (mmHg) 
 
MI/LV (%) 
 
 
4±1* 
 
114±5* 
 
 
 
4±2* 
 
120±6* 
 
 
  
26±2 
 
100±3 
 
43±3 
 
19±1‡ 
 
87±5 
 
46±5 
 
22±1 
 
98±3 
 
36±3 
 
17±1† 
 
88±5 
 
40±3 
Pressures were measured at the end of the intervention period, whereas infarct size was 
measured one week after surgery. LVEDP: left ventricular end-diastolic pressure; LVPSP: left 
ventricular peak-systolic pressure; MI/LV: size of myocardial infarction (MI relative to the 
left ventricle (LV). HF: heart failure; SED: sedentary; PL: placebo; EX: exercise training; 
LOS: losartan. Sham vs. HF: * p<0.01; HF-EX-LOS vs. HF-SED-PL: † p<0.01; HF-SED-
LOS vs. HF-SED-PL: ‡ p<0.05.  
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FIGURE LEGENDS 
 
Figure 1. Maximal oxygen uptake (VO2max) as a measure of exercise capacity. VO2max in 
sham-operated (SH) rats was 40% higher (* p<0.01) than in those with heart 
failure (HF) before the exercise training program (pre-test). Post-tests indicated 
that VO2max increased 40% by exercise training (EX) in SH and HF rats; † 
(p<0.01), and by 20% in losartan (LOS)-treated sedentary (SED) HF rats 
compared to placebo (PL)-controlled HF rats; ≠ (p<0.01), respectively. Note that 
HF EX PL and HF EX LOS curves sit on top of each other. Also, SH SED PL 
and HF SED PL rats decreased VO2max from pre-to post-tests; # (p<0.05).  
 
Figure 2. A: Heart failure (HF) reduced the acetylcholine (Ach)-mediated vasorelaxation 
of aorta as indicated by the right shifted dose-response curve of sedentary (SED) 
HF rats on placebo (PL), whereas exercise training and losartan corrected for 
this dysfunction. B: Sensitivity to acetylcholine (EC50); note the y-axis has a 
logarithmic scale. Aorta segments of the SED HF rats relaxed less than all the 
other groups (* p<0.05). Interventions with exercise training (EX), losartan 
(LOS) or a combination of both (EX LOS) improved endothelial sensitivity to 
Ach to levels comparable with SED sham-operated (SH) rats, whereas SH EX 
rats exceeded SED SH rats († p<0.01). C: Maximal vasorelaxation was increased 
in LOS-treated SED HF rats compared to PL-controlled SED HF rats (* p<0.05). 
D: EC50-values of Ach-mediated vasorelaxation (white and black bars), with 
delta EC50-values (grey bars) indicating difference in Ach-mediated 
vasorelaxation after addition of 3 mM L-arginine; this maneuver increased the 
response in HF-SED-PL (* p<0.05). E: EC50-values of Ach-mediated 
vasorelaxation (white and black bars), with delta EC50-values (grey bars) 
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indicating difference in Ach-mediated vasorelaxation after addition of 250 IU 
superoxide dismutase (SOD); this maneuver increased the responses in SH-SED-
PL and HF-SED-PL (* p<0.05 and † p<0.01).  
  
Figure 3. A: Acetylcholine (Ach)-mediated vasorelaxation in the presence of 10-5 M 
indomethacin (Indo). B: Ach-mediated vasorelaxation in the presence of 10-4 M 
LNNA and 10-5 M Indo, with a trend (p=0.12) towards an increase in 
vasorelaxation in the heart failure (HF) rats on losartan (LOS) vs. placebo (PL)-
controlled sedentary (SED) or exercise training (EX) HF or sham-operated (SH) 
rats. C: Ach-mediated vasorelaxation in the presence of 10-5 M ODQ and 10-5 M 
Indo. D: Vasorelaxation due to nitric oxide (NO) was calculated by subtracting 
the area under curve (AUC) of the graphs in panels B and C from the AUC of 
panel A (A-(B+C)). HF-EX-LOS vs. HF-SED-PL and HF-SED-LOS: * p<0.05; 
SH-EX-PL and HF-EX-PL vs. HF-SED-LOS, HF-SED-PL and SH-SED-PL: † 
p<0.01. 
 
 
 
